Differential metabolites facilitate metabolic dysfunction-associated fatty liver disease malignancy via immune evasion and M2-polarized macrophages

Figure 2 Dynamic alterations in hepatic differential metabolites during metabolic dysfunction-associated fatty liver disease malignancy. A and B: Differential metabolite (DM) volcano maps (P value vs fold change). Metabolic dysfunction-associated fatty liver disease (MAFLD) vs normal control (NC) (A). Hepatocellular carcinoma (HCC) vs metabolic dysfunction-associated steatohepatitis (MASH) (B); C and D: Principal least squares-discriminant analysis of DM. MAFLD vs NC (C). HCC vs MASH (D); E and F: S-shaped orthogonal principal least squares-discriminant analysis plot analysis of DM. MAFLD vs NC (E) and HCC vs MASH (F). NC: Normal control; MAFLD: Metabolic dysfunction-associated fatty liver disease; FC: Fold change; PLS-DA: Principal least squares-discriminant analysis; Splot-OPLS-DA: S-shaped orthogonal principal least squares-discriminant analysis plot analysis.